Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References CosentyxⓇ grew 22% in Q3; label expansion with pediatric approvals Sales evolution USD m, % cc Ex-US +22% US 1.2bn 1.0bn 494 372 640 753 Q3 2020 Q3 2021 +18% 3.5bn 1.4bn 2.9bn 1.1bn 1.8bn 2.1bn 9M 2021 Strong growth across core indications and markets ■ US: growing volume in line with market across indications vs. Q2 ■ EU: leading biologic in PsO, leading originator biologic in SpA¹ Expanding clinical differentiation with pediatric approvals ■ Ped PSO approval in China 75mg PFS approval in EU for patients <50kg ■ JPSA and ERA indications granted priority review by FDA 9M 2020 Ped PSO Pediatric Psoriasis PsO - Psoriasis SpA - Spondyloarthritis PFS - Pre-filled Syringe jPsA - Juvenile psoriasis arthritis ERA-Enthesitis related rheumatoid arthritis 1. EU patient share data June 2021. 25 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation